“…Of the 64 studies included in the review (Table 1), most (61%) were set in the clinical environment, 72-110 with the vast majority of studies conducted in the US (39%), 42,79,80,83-90,93,95,97,98,104,106,108,111-117 Sweden (13%), 75,77,78,99,100,102,110,118 Japan (9%), 82,91,109,119-121 South Korea 96,122-124 and the UK (6% each). 72,103,107,125 Nearly half of the studies were randomized controlled trials, 42,73,74,77,78,80,84-90,95,98,99,101,105-108,112,115,116,120,123,124,126-128 and there were slightly fewer studies involving patients (45%) 72-75,77-80,82,84-87,89,90,92,95-99,101,103,106-108,110,113,129 as opposed to healthy participants. The largest group of patients were those with cancer.…”